Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Clinton Baird

Neurological Surgery Tulsa, OK Medical Doctor

NPI 1972656908 CMS profile 362032

6130 E 81St St, Tulsa, OK 74137

Open in the dashboard

General payments

$621,288

21 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Clinton Baird of Tulsa, OK is reported in the CMS Open Payments database as having received $621,288 across 21 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Neurological Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $326 8
2024 General $141 1
2023 General $200,129 2
2022 General $200,020 2
2021 General $220,559 3
2020 General $61 3
2019 General $52 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Clinton Baird
  • Neurological Surgery median
  • Middle half of Neurological Surgery
  • National median

In program year 2025, general payments to Clinton Baird were reported at $326. Among 5,467 Neurological Surgery profiles paid that year, the median was $596 and the middle half received between $159 and $3,102.

Show as a table
Year Clinton Baird Neurological Surgery median Middle half National median
2019 $52 $582 $138–$3,006 $163
2020 $61 $294 $76–$2,174 $114
2021 $220,559 $387 $105–$2,432 $132
2022 $200,020 $542 $139–$2,989 $149
2023 $200,129 $534 $145–$2,697 $160
2024 $141 $574 $155–$3,046 $164
2025 $326 $596 $159–$3,102 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Omnia Medical, LLC $620,500 4 payments
  2. DePuy Synthes Sales Inc. $147 1 payment
  3. Abbott Laboratories $141 1 payment
  4. Boston Scientific Corporation $129 1 payment
  5. Providence Medical Technology, Inc. $67 1 payment
  6. Zimmer Biomet Holdings, Inc. $59 1 payment
  7. Orthofix Medical, Inc. $50 4 payments
  8. Medtronic USA, Inc. $40 2 payments
  9. Globus Medical, Inc. $39 1 payment
  10. Alphatec Spine, Inc $29 1 payment
  11. Other $89 4 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Acquisitions $600,000 3 payments
  2. Consulting Fee $20,500 1 payment
  3. Food and Beverage $788 17 payments
Products named General payments · program years 2019–2025
  1. Velys $147 1 payment
  2. PROCLAIM $141 1 payment
  3. Lineum Posterior Cervical $59 1 payment
  4. Cervical-Stim $50 4 payments
  5. INTELLIS $40 2 payments
  6. SABLE $39 1 payment
  7. SQUADRON $29 1 payment
  8. VISTASEAL $24 1 payment
  9. CUSA CLARITY $24 1 payment
  10. DURAGEN $24 1 payment
  11. Other $112 5 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 34 drugs

Part D claims

2,741

Median for Neurosurgery: 83

Drug cost

$122,521

Median for Neurosurgery: $872

Branded share of claims

55.3%

Median for Neurosurgery: 16.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 684 $21,945
Belbuca Buprenorphine Hcl Brand 24 $20,997
Buprenorphine Generic 65 $17,227
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 564 $17,037
Xtampza Er Oxycodone Myristate Brand 31 $13,923
Oxycodone Hcl Generic 344 $6,257
Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl Brand 21 $5,094
Buprenorphine Hcl Generic 104 $3,987
Morphine Sulfate Er Morphine Sulfate Brand 124 $3,745
Pregabalin Generic 193 $3,201

The 10 drugs with the highest cost, of 34 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,779 Part D prescribers listed as Neurosurgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 71 billing codes

Paid by Medicare

$305,414

Medicare's payments for the services billed

Medicare patients

524

Average age 69

Services billed

2,909

296 women, 228 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 73%
Depression 43%
Diabetes 37%
Ischemic heart disease 32%
Heart failure 29%
Chronic kidney disease 27%
COPD 27%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

21 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record